The reactive oxygen species-sensitive nanomedicines can effectively alleviate stroke pathology by controlling the release of therapeutic agents, inhibiting the translocation of nuclear HMGB1, and modulating microglial polarization to reduce infarct volume and enhance neurogenesis [63, 182]. The gene discussed is HMGB1; the disease is stroke disorder.